ArticleScientific reports2026
Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children and adolescents with classical Hodgkin lymphoma have a progression-free survival (PFS) rate of ≥ 90% with current treatments. The current challenge is to reduce adverse late-effects while maintaining high survival. Distinguishing lung involvement (Stage IV) from benign lung lesions remains a staging challenge in pediatric Hodgkin lymphoma (pHL). This study analyzed the prevalence, morphological patterns, and prognostic impact of lung lesions on progression-free survival (PFS) within the EuroNet-PHL-C1 trial. A retrospective analysis was conducted on chest CT scans from 1,298 pHL patients enrolled in the EuroNet-PHL-C1 trial. Patients were stratified by established treatment groups (TG-1, TG-2, TG-3). Lesions were classified by morphological pattern, and Kaplan-Meier analysis was used to compare 60-month PFS between groups with and without lung lesions. Lung lesions were identified in 60.2% (782/1298) of patients, with nodules being the predominant pattern (89%). In the combined TG-1 and TG-2 cohort (early/intermediate stages), the presence of any lung lesion correlated with significantly lower 5-year PFS (85.5% vs. 91.7%; p = 0.0197). Importantly, this lower PFS was driven by non-nodule morphologies. In the TG-3 (advanced stage) cohort, neither the presence of lung lesions nor stage IV classification significantly affected PFS. Lung lesions are highly prevalent in pHL. However, the presence of pulmonary nodules does not confer an inferior prognosis. The prognostic impact of lung lesions is primarily limited to non-nodule patterns in early-stage disease. These findings suggest that incorporating morphological patterns may be beneficial for refining risk stratification in future pHL trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.